Literature DB >> 18657100

What ever happened to FDAMA Section 114? A look back after 10 years.

Peter J Neumann.   

Abstract

Mesh:

Year:  2008        PMID: 18657100     DOI: 10.1111/j.1524-4733.2008.00429.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  2 in total

1.  US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness research.

Authors:  Peter J Neumann; Pei-Jung Lin; Tom E Hughes
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

2.  Should off-label drugs be included as comparators in pharmacoeconomic studies?

Authors:  Surrey M Walton; Glen T Schumock
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.